Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Roivant

Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d

Immunovant Q4 Earnings Call Highlights

Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna. Matthew Klein, CEO of Roivant, said the company has had “a pret

This Red-Hot Biopharma Stock Could Fizzle Out Soon

This Red-Hot Biopharma Stock Could Fizzle Out Soon

Roivant Sciences (ROIV) shows strong technical momentum and is trading at new all-time highs. Shares are up 52% over the past year and 20% in the last month. ROIV has a 100% “Buy” opinion from Barchart and a Trend Seeker “Buy” signal. Despite the price gains, Roivant lacks consistent revenue...

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Vivek Ramaswamy is furiously defending his business ties in China. What are they?

‘Vivek’s first business had a subsidiary in China’ which was closed ‘as the risks of doing business in China became apparent,’ Ramaswamy spokesperson says

The Independent UK

Smoke and mirrors: I’ve been debating Vivek Ramaswamy for 2 years. Here’s how I got past his diversionary tactics

Vivek Ramaswamy's fiercest critic, Yale Professor Jeffrey Sonnenfeld, has studied the presidential hopeful's debate strategies–and his business record.

Vivek Ramaswamy: The mini Trump making waves in the Republican contest

Broadly viewed as the winner of the Republican presidential debate, the ‘anti-woke’ tech bro has broken out from the GOP pack

Evening Standard

‘He’s an insider’: Ramaswamy’s deep ties to rightwing kingpins revealed

Republican candidate brands himself as an ‘outsider’ but has close links to prominent figures Leonard Leo and Peter Thiel

The Guardian - US

inkl

Read news from The Economist, FT, and more,
with one subscription

How Vivek Ramaswamy, the surprise GOP debate star, made his fortune and triggered his critics

How Vivek Ramaswamy, the surprise GOP debate star, made his fortune and triggered his critics

He bills himself as an iconoclast ready to shake up the Republican Party after making millions trying to do the same in the biotech industry.

Vivek Ramaswamy is threatening GOP heavyweights in the polls–but his business record doesn't live up to the hype

Vivek Ramaswamy is threatening GOP heavyweights in the polls–but his business record doesn't live up to the hype

Yale's Sonnenfeld and Tian retrace presidential hopeful Vivek Ramaswamy's business record.

Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases

Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases

Roivant Sciences Ltd (NASDAQ:ROIV) and Pfizer Inc (NYSE:PFE) unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant was established in September 2021 through a transaction between Roivant and Pfizer. Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25%…

1

People

198,290 stories

Vivek Ramaswamy

Tricia McLaughlin

Jeffrey Sonnenfeld

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Republican Party

the White House

Harvard University

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Rheumatoid Arthritis

Places

390,112 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play